

# Special Issue

## Liquid Biopsy in Breast Cancer

### Message from the Guest Editors

This Special Issue of *Cancers* welcomes contributions that present new data and address or discuss liquid biopsy biomarkers with prognostic and/or predictive relevance in BC. This Special Issue will also focus on translational research that will shed light onto the role of CTCs and other liquid biopsy analytes in BC metastatic progression, as well as resistance to endocrine therapy, chemotherapy, or targeted therapies. Studies including the development of new liquid biopsy assays are also welcome. Of great interest are reports on the longitudinal assessment of liquid biopsy, as well as studies utilizing liquid biopsy to identify potential novel therapeutic targets. For further reading, please follow the link to the Special Issue Website at: [https://www.mdpi.com/journal/cancers/special\\_issues/Liquid\\_Biopsy\\_Breast\\_Cancer](https://www.mdpi.com/journal/cancers/special_issues/Liquid_Biopsy_Breast_Cancer)

### Guest Editors

Prof. Dr. Dimitrios Mavroudis

Head, Department of Medical Oncology, University of Crete Medical School, Heraklion, Greece

Dr. Maria Papadaki

Laboratory of Translational Oncology, School of Medicine, University of Crete, Heraklion, Greece

### Deadline for manuscript submissions

closed (30 September 2023)



# Cancers

an Open Access Journal  
by MDPI

Impact Factor 4.5  
CiteScore 8.0  
Indexed in PubMed



[mdpi.com/si/108007](https://www.mdpi.com/si/108007)

*Cancers*  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://www.mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.5  
CiteScore 8.0  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)